When is high-dose intravenous iron repletion needed? Assessing new treatment options

Drug Design, Development and Therapy

Volumn , Issue 5, 2011, Pages 51-60

  Gozzard, David ^a  

^a BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

Erythropoiesis; High dose; Intravenous iron; Iron deficiency; Iron deficiency anemia; Iron isomaltoside 1000; Single dose

Indexed keywords

ANTIANEMIC AGENT; FERRIC CARBOXYMALTOSE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERUMOXYTOL; HEMOGLOBIN; IRON; IRON ISOMALTOSIDE 1000; TRANSFERRIN; UNCLASSIFIED DRUG; DISACCHARIDE; DRUG DERIVATIVE; FERRIC ION; MALTOSE;

ANEMIA; BLOOD TRANSFUSION; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; ENTERITIS; FERRITIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON STORAGE; IRON THERAPY; MENORRHAGIA; NEOPLASM; NONHUMAN; OBSTETRICS; PATIENT COMPLIANCE; QUALITY OF LIFE; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; SUPPLEMENTATION; ANIMAL; BLEEDING; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION;

ANEMIA, IRON-DEFICIENCY; ANIMALS; DISACCHARIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FERRIC COMPOUNDS; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; IRON; MALTOSE;

EID: 79952903667     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S15817     Document Type: Review

References (62)

1. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Hematol. 2009;122(2-3):78-86.
2. Craig R, Mindell J, editors. Health Survey for England 2005: The Health of Older People. Volume 1. London: TSO; 2007.
3. De Benoist B, McLean E, Egli I, Cogswell M, editors. Worldwide Prevalence of Anemia 1993-2005: WHO Global Database on Anemia. Geneva: World Health Organisation; 2005.
4. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11:530-538.
5. Melamed N, Ben-Haroush A, Kaplan B, Yogev Y. Iron supplementation in pregnancy - does the preparation matter? Arch Gynecol Obstet. 2007;276(6):601-604.
6. Lawrence R. Development and comparison of iron dextran products. PDA J Pharm Sci Technol. 1998;52(5):190-197.
7. Venofer®[Package insert]. Surrey, UK: Syner-med Pharmaceutical Products Ltd; 2010.
8. Cosmofer®[Package insert]. Holbaek, Denmark: Pharmacosmos A/S; 2010.
9. Ferrlecit® [Monograph]. Bridgewater, NJ: Sanofi-aventis US LLC; 2010.
10. Feraheme®[Monograph]. Cambridge, MA: AMAG Pharmaceuticals Inc; 2009.
11. Ferinject®[Package insert]. Surrey, UK: Syner-med Pharmaceutical Products Ltd; 2010.
12. Monofer®[Package insert]. Cambridge, MA: AMAG Pharmaceuticals Inc; 2010.
13. Peebles G, Stanley S. Evaluation of service reconfiguration for managing intravenous iron supplementation in non-hemodialysis patients with chronic renal failure. Journal of Outcomes Research. 2004;8: 15-25.
14. Jenkins A. Using iron dextran to treat iron-deficiency anemia. Hospital Pharmacist. 2005;12(6):224-225.
15. Auerbach M, Coyne D, Ballard H. Intravenous iron: From anathema to standard of care. Am J Hematol. 2008;83(7):580-588.
16. Agarwal R. Individualizing decision-making - resurrecting the doctorpatient relationship in the anemia debate. Clin J Am Soc Nephrol. 2010; 5(7):1340-1346.
17. The Renal Association. Clinical Practice Guidelines: Chronic Kidney Disease. Hampshire, UK: The Renal Association; 2010.
18. Jungers, P., Qualim Z, Nguyen-Khoa T, Massey Z, London G. Cardioprotection: An essential component for predialysis chronic renal failure treatment. Nephrologie. 2003;24(2):79-88. French.
19. Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: Oral or intravenous? Curr Med Res Opin. 2010;26(2):473-482.
20. Ganzoni AM. Schweiz Med Wochenschr. 1970;100(7):301-303. German. [Intraverous iron-deptran: therapeutic and experimental possibilities]. [German]
21. Peebles G, Fenwick S. Intravenous iron administration in a short-stay hospital setting. Nurs Stand. 2008;22(48):35-41.
22. Gasche C, Lomer MCE, Cavill, Weiss G. Iron, anemia, and inflammatory bowel disease. Gut. 2004;53:1190-1197.
23. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(12):1545-1553.
24. Bothwell TH. Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr. 2000;72(1):S257-S264.
25. National Institute for Health and Clinical Excellence. Antenatal care: Routine Care for the Healthy Pregnant Woman. Clinical Guideline. London, UK: National Institute for Health and Clinical Excellence; 2008.
26. Bashiri A, Smolin A, Sheiner E, Zelingher J, Mazor M. Maternal rehospitalization after singleton term vaginal delivery. J Matern Fetal Neonatal Med. 2003;14(5):344-348.
27. Knight M, Callaghan WM, Berg C, et al. Trends in postpartum hemorrhage in high resource countries: A review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth. 2009;9:55.
28. Royal College of Obstetricians and Gynecologists. National Sentinel Caesarean Section Audit (England, Wales and Northern Ireland). London, UK: Royal College of Obstetricians and Gynecologists Press; 2001.
29. Breymann C. The use of iron sucrose complex for anemia in pregnancy and the postpartum period. Semin Hematol. 2006;43 Suppl 6: S28-S31.
30. Bodnar LM, Siega-Riz AM, Miller WC, Cogswell ME, McDonald T. Who should be screened for postpartum anemia? An evaluation of current recommendations. Am J Epidemiol. 2002;156(10): 903-912.
31. Hallak M, Sharon AS, Diukman R, Auslender R, Abramovici H. Supplementing iron intravenously in pregnancy. A way to avoid blood transfusions. J Reprod Med. 1997;42(2):99-103.
32. Qunibi W, Dinh Q, Benjamin J. Safety and tolerability profile of ferric carboxymaltose (FCM) a new high dose intravenous iron, across ten multi-center trials. J Am Soc Nephrol. 2007;18:SU-PO1029.
33. Protheroe J. Modern management of menorrhagia. J Fam Plann Reprod Health Care. 2004;30(2):118-122.
34. Oehler MK, Rees MC. Menorrhagia: An update. Acta Obstet Gynecol Scand. 2003;82(5):405-422.
35. Morrison J, Patel ST, Watson W, Zaidi QR, Mangione A, Goss TF. Assessment of the prevalence and impact of anemia on women hospitalized for gynecologic conditions associated with heavy uterine bleeding. J Reprod Med. 2008;53(5):323-330.
36. Lo L. Modern management of menorrhagia. Hong Kong Practitioner. 1996;18(2):62-66.
37. Prentice A. Medical management of menorrhagia. BMJ. 1999;319: 1343-1345.
38. National Institute for Health and Clinical Excellence. Heavy Menstrual Bleeding. Clinical Guideline. London, UK: National Institute for Health and Clinical Excellence; 2007.
39. Kim YH, Chung HH, Kang SB, Kim SC, Kim YT. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: A phase IV, open label, prospective, randomized study. Acta Haematol. 2009;121(1):37-41.
40. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial. Transfusion. 2009;49(12):2719-2728.
41. Bokemeyer C, Aapro MS, Courdi A, et al. European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer. Eur J Cancer. 2004;40(15):2201-2216.
42. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin-alfa therapy. Cancer. 2002;95(4): 888-895.
43. Weiss G. Pathogenesis and treatment of anemia of chronic disease. Blood Rev. 2002;16(2):87-96.
44. Auerbach M. Should intravenous iron be the standard of care in oncology. J Clin Oncol. 2008;26(10):1579-1581.
45. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26(1):41-46.
46. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy related anemia: A multicenter, open label, randomized trial. J Clin Oncol. 2004;22(7):1301-1307.
47. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate improves response to epoietin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12(2):231-242.
48. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoietin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;26(10): 1611-1618.
49. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoietin alfa. J Clin Oncol. 2008;26(10):1619-1625.
50. American Society of Clinical Oncology. Important information for physicians about changes affecting the FDA-approved use of erythropoiesis stimulating agents (ESA). Available from: http://www.asco.org/ASCO/ArticleASCO/Cancer%20Policy%20and%20Clinical%20Affairs/Policy/MMA%20Regulation%20&%20Resources/erythropoieticstimulatingagents%20Doc%20for%20Practicing%20Oncologists%20092508%20FINAL.pdf.Accessed Jun 8 2010.
51. Steensma DP. Is anemia of cancer different from chemotherapy induced anemia? J Clin Oncol. 2008;26(7):1022-1024.
52. Singh AK, Tang KL, Bamhart H, et al. CHOIR investigators. Correction of anemia with epoietin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
53. National Institute for Health and Clinical Excellence. Erythropoietin analogues for anemia caused by cancer treatment. Technology appraisal guidance. London, UK: National Institute for Health and Clinical Excellence; 2008.
54. Aapro MS, Link H. September 2007 Update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008;13 Suppl 3:33-36.
55. Steensma DP. New ASH/ASCO guidelines on the use of erythropoiesisstimulating agents: A chorale amid cacophony. J Support Oncol. 2007; 5(10):471-473.
56. Special Eurobarometer. Health and Food. 246/Wave 64.3 - TNS Opinion and Social. European Commission; 2006.
57. Portier K, Tolson JK, Roberts SM. Body weight distributions for risk management. (NHANES 1999-2002). Risk Anal. 2007;27(1):11-26.
58. European Pharmacopoeia-Monograph. Page 1408.
59. Luitpold Pharmaceuticals Inc. (19th July 2007). Methods and Compositions for Administration of Iron. WO2007/081744 A2.
60. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182-1192.
61. Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010;85(9):650-654.
62. Chertow GM, Winkelmayer WC. On the relative safety of intravenous iron formulations: New answers, new questions. Am J Hematol. 2010; 85(9):643-644.